DNA copy number alterations mark disease progression in paediatric chronic myeloid leukaemia

Naomi E van der Sligte; Manuela Krumbholz; Agata Pastorczak; Blanca Scheijen; Josephine T Tauer; Christina Nowasz; Edwin Sonneveld; Geertruida H de Bock; Tiny G J Meeuwsen-de Boer; Simon van Reijmersdal; Roland P Kuiper; Jutta Bradtke; Markus Metzler; Meinolf Suttorp; Evelina S J M de Bont; Frank N van Leeuwen

doi:10.1111/bjh.12850

DNA copy number alterations mark disease progression in paediatric chronic myeloid leukaemia

Naomi E van der Sligte, Manuela Krumbholz, Agata Pastorczak, Blanca Scheijen, Josephine T Tauer, Christina Nowasz, Edwin Sonneveld, Geertruida H de Bock, Tiny G J Meeuwsen-de Boer, Simon van Reijmersdal, Roland P Kuiper, Jutta Bradtke, Markus Metzler, Meinolf Suttorp, Evelina S J M de Bont, Frank N van Leeuwen

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Early recognition of children with chronic phase chronic myeloid leukaemia (CML-CP) at risk for developing a lymphoid blast crisis (LyBC) is desirable, because therapy options in CML-LyBC are limited. We used Multiplex Ligation-dependent Probe Amplification to determine whether B-cell lymphoid leukaemia-specific copy number alterations (CNAs) (e.g. IKZF1, PAX5, CDKN2A deletions) could be detected in CML-CP and may be used to predict disease progression to LyBC. CNAs were detected in all patients with CML-LyBC, but in none of the 77 patients with CML-CP. Based on this study we conclude that CNAs remain a hallmark of disease progression.

Original language	English
Pages (from-to)	250-3
Number of pages	4
Journal	British journal of haematology
Volume	166
Issue number	2
DOIs	https://doi.org/10.1111/bjh.12850
Publication status	Published - Jul 2014
Externally published	Yes

Keywords

Biomarkers, Tumor/genetics
Blast Crisis/genetics
Child
DNA Copy Number Variations/genetics
DNA, Neoplasm/genetics
Disease Progression
Early Diagnosis
Humans
Ikaros Transcription Factor/genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
Molecular Sequence Data
Multiplex Polymerase Chain Reaction/methods
Neoplasm Proteins/genetics
Point Mutation
Prognosis

Access to Document

10.1111/bjh.12850

Cite this

van der Sligte, N. E., Krumbholz, M., Pastorczak, A., Scheijen, B., Tauer, J. T., Nowasz, C., Sonneveld, E., de Bock, G. H., Meeuwsen-de Boer, T. G. J., van Reijmersdal, S., Kuiper, R. P., Bradtke, J., Metzler, M., Suttorp, M., de Bont, E. S. J. M., & van Leeuwen, F. N. (2014). DNA copy number alterations mark disease progression in paediatric chronic myeloid leukaemia. British journal of haematology, 166(2), 250-3. https://doi.org/10.1111/bjh.12850

@article{0da0fa81cd25491b89a616e6fe4ae2e3,

title = "DNA copy number alterations mark disease progression in paediatric chronic myeloid leukaemia",

abstract = "Early recognition of children with chronic phase chronic myeloid leukaemia (CML-CP) at risk for developing a lymphoid blast crisis (LyBC) is desirable, because therapy options in CML-LyBC are limited. We used Multiplex Ligation-dependent Probe Amplification to determine whether B-cell lymphoid leukaemia-specific copy number alterations (CNAs) (e.g. IKZF1, PAX5, CDKN2A deletions) could be detected in CML-CP and may be used to predict disease progression to LyBC. CNAs were detected in all patients with CML-LyBC, but in none of the 77 patients with CML-CP. Based on this study we conclude that CNAs remain a hallmark of disease progression. ",

keywords = "Biomarkers, Tumor/genetics, Blast Crisis/genetics, Child, DNA Copy Number Variations/genetics, DNA, Neoplasm/genetics, Disease Progression, Early Diagnosis, Humans, Ikaros Transcription Factor/genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics, Molecular Sequence Data, Multiplex Polymerase Chain Reaction/methods, Neoplasm Proteins/genetics, Point Mutation, Prognosis",

author = "{van der Sligte}, {Naomi E} and Manuela Krumbholz and Agata Pastorczak and Blanca Scheijen and Tauer, {Josephine T} and Christina Nowasz and Edwin Sonneveld and {de Bock}, {Geertruida H} and {Meeuwsen-de Boer}, {Tiny G J} and {van Reijmersdal}, Simon and Kuiper, {Roland P} and Jutta Bradtke and Markus Metzler and Meinolf Suttorp and {de Bont}, {Evelina S J M} and {van Leeuwen}, {Frank N}",

note = "{\textcopyright} 2014 John Wiley & Sons Ltd.",

year = "2014",

month = jul,

doi = "10.1111/bjh.12850",

language = "English",

volume = "166",

pages = "250--3",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

van der Sligte, NE, Krumbholz, M, Pastorczak, A, Scheijen, B, Tauer, JT, Nowasz, C, Sonneveld, E, de Bock, GH, Meeuwsen-de Boer, TGJ, van Reijmersdal, S, Kuiper, RP, Bradtke, J, Metzler, M, Suttorp, M, de Bont, ESJM & van Leeuwen, FN 2014, 'DNA copy number alterations mark disease progression in paediatric chronic myeloid leukaemia', British journal of haematology, vol. 166, no. 2, pp. 250-3. https://doi.org/10.1111/bjh.12850

TY - JOUR

T1 - DNA copy number alterations mark disease progression in paediatric chronic myeloid leukaemia

AU - van der Sligte, Naomi E

AU - Krumbholz, Manuela

AU - Pastorczak, Agata

AU - Scheijen, Blanca

AU - Tauer, Josephine T

AU - Nowasz, Christina

AU - Sonneveld, Edwin

AU - de Bock, Geertruida H

AU - Meeuwsen-de Boer, Tiny G J

AU - van Reijmersdal, Simon

AU - Kuiper, Roland P

AU - Bradtke, Jutta

AU - Metzler, Markus

AU - Suttorp, Meinolf

AU - de Bont, Evelina S J M

AU - van Leeuwen, Frank N

PY - 2014/7

Y1 - 2014/7

N2 - Early recognition of children with chronic phase chronic myeloid leukaemia (CML-CP) at risk for developing a lymphoid blast crisis (LyBC) is desirable, because therapy options in CML-LyBC are limited. We used Multiplex Ligation-dependent Probe Amplification to determine whether B-cell lymphoid leukaemia-specific copy number alterations (CNAs) (e.g. IKZF1, PAX5, CDKN2A deletions) could be detected in CML-CP and may be used to predict disease progression to LyBC. CNAs were detected in all patients with CML-LyBC, but in none of the 77 patients with CML-CP. Based on this study we conclude that CNAs remain a hallmark of disease progression.

AB - Early recognition of children with chronic phase chronic myeloid leukaemia (CML-CP) at risk for developing a lymphoid blast crisis (LyBC) is desirable, because therapy options in CML-LyBC are limited. We used Multiplex Ligation-dependent Probe Amplification to determine whether B-cell lymphoid leukaemia-specific copy number alterations (CNAs) (e.g. IKZF1, PAX5, CDKN2A deletions) could be detected in CML-CP and may be used to predict disease progression to LyBC. CNAs were detected in all patients with CML-LyBC, but in none of the 77 patients with CML-CP. Based on this study we conclude that CNAs remain a hallmark of disease progression.

KW - Biomarkers, Tumor/genetics

KW - Blast Crisis/genetics

KW - Child

KW - DNA Copy Number Variations/genetics

KW - DNA, Neoplasm/genetics

KW - Disease Progression

KW - Early Diagnosis

KW - Humans

KW - Ikaros Transcription Factor/genetics

KW - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics

KW - Molecular Sequence Data

KW - Multiplex Polymerase Chain Reaction/methods

KW - Neoplasm Proteins/genetics

KW - Point Mutation

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84903698207&partnerID=8YFLogxK

U2 - 10.1111/bjh.12850

DO - 10.1111/bjh.12850

M3 - Article

C2 - 24673583

SN - 0007-1048

VL - 166

SP - 250

EP - 253

JO - British journal of haematology

JF - British journal of haematology

IS - 2

ER -

DNA copy number alterations mark disease progression in paediatric chronic myeloid leukaemia

Abstract

Keywords

Access to Document

Fingerprint

Cite this